SuperSonic signs distribution agreement with Hologic to develop breast ultrasound market in the U.S

September 02, 2015

In this article, Uckun and his colleagues demonstrate for the first time that leukemic cells taken from ALL patients overexpress a number of proteins involved in the JAK3 signaling pathway and their receptors, leading to increased JAK3 activation. Analysis of eight previous studies revealed that this amplified expression of JAK3-stimulatory proteins, along with a deficiency of JAK3-inhibitory signaling proteins, occurs in vivo in a number of B-lineage malignancies. Therefore, despite the rarity of JAK3-activating mutations it appears that JAK3 is permanently active in many B-lineage lymphoid malignancies, including ALL, and is an exciting target for novel therapeutic approaches.

The authors conclude that clinical studies are warranted to evaluate the activity of JAK3 inhibitors in B-lineage leukemia, in order to elucidate their activity and side-effect profiles.

ABOUT Expert Review of Anticancer Therapy Expert Review of Anticancer Therapy provides expert analysis and commentary on the performance of new therapeutic and diagnostic modalities in this new era for oncology.

Areas covered include:

??? Therapeutic overviews of specific cancers ??? Performance and benefits of newly approved anticancer agents ??? New therapeutic indications ??? Adverse effects ?? occurrence and reduction ??? Prospects for medicines in late-stage trials approaching regulatory approval ??? Combined approaches of chemotherapy and radiotherapy ??? Epidemiologic studies highlighting prospects for cancer prevention and control ??? New diagnostic approaches to screening and patient stratification

Expert Review of Anticancer Therapy provides a centralized resource of commentary and debate to inform clinical and economic decision-making in healthcare delivery.